Recombinant human interleukin-11 (Shanghai CP Guojian)

重组人白介素-11（中信国健）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-11 (Shanghai CP Guojian)
Drug Alias Nameoprelvekin follow-on biologic奥普瑞生物类似药欣美格
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterleukin 11 receptor alpha stimulants
TargetsInterleukin 11 receptor alpha
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryMainland China
Original Approved Date2005/04/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AC02
Related LinksN/A